Global Opioid-Induced Constipation Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Opioid-Induced Constipation market size will reach 3,128.22 Million USD in 2025 and is projected to reach 4,308.67 Million USD by 2032, with a CAGR of 4.68% (2025-2032). Notably, the China Opioid-Induced Constipation market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Opioid-induced constipation (OIC) is a common and distressing side effect associated with the use of opioid medications for pain management. Opioids, which include prescription medications like morphine and oxycodone, as well as illicit drugs such as heroin, can slow down the digestive system and lead to infrequent, difficult, and painful bowel movements. OIC can cause significant discomfort, impact a person's quality of life, and, if left untreated, may result in serious complications such as bowel blockages. Healthcare providers often recommend various treatments, including lifestyle changes, dietary modifications, and specific medications, to alleviate OIC and improve the overall well-being of individuals on opioid therapy while ensuring effective pain management.
The major global manufacturers of Opioid-Induced Constipation include Ironwood Pharmaceuticals, Daiichi Sankyo, Pfizer, Progenics Pharmaceuticals, Shionogi, Allergan, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma, Mundipharma International, Ono Pharmaceutical, Takeda Pharmaceutical Company, Theravance Biopharma, Bausch Health, Cosmo Pharmaceuticals, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Opioid-Induced Constipation. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Opioid-Induced Constipation market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Opioid-Induced Constipation market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Opioid-Induced Constipation industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Opioid-Induced Constipation Include:
Ironwood Pharmaceuticals
Daiichi Sankyo
Pfizer
Progenics Pharmaceuticals
Shionogi
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International
Ono Pharmaceutical
Takeda Pharmaceutical Company
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Opioid-Induced Constipation Product Segment Include:
Lubiprostone
Methylnaltrexone Bromide
Naldemedine
Alvimopan
Others
Opioid-Induced Constipation Product Application Include:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Opioid-Induced Constipation Industry PESTEL Analysis
Chapter 3: Global Opioid-Induced Constipation Industry Porter's Five Forces Analysis
Chapter 4: Global Opioid-Induced Constipation Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis
Chapter 5: Global Opioid-Induced Constipation Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 6: Global Opioid-Induced Constipation Sales, Revenue, Price and Forecast by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 8: Industrial Chain Analysis, Opioid-Induced Constipation Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Opioid-Induced Constipation market size will reach 3,128.22 Million USD in 2025 and is projected to reach 4,308.67 Million USD by 2032, with a CAGR of 4.68% (2025-2032). Notably, the China Opioid-Induced Constipation market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Opioid-induced constipation (OIC) is a common and distressing side effect associated with the use of opioid medications for pain management. Opioids, which include prescription medications like morphine and oxycodone, as well as illicit drugs such as heroin, can slow down the digestive system and lead to infrequent, difficult, and painful bowel movements. OIC can cause significant discomfort, impact a person's quality of life, and, if left untreated, may result in serious complications such as bowel blockages. Healthcare providers often recommend various treatments, including lifestyle changes, dietary modifications, and specific medications, to alleviate OIC and improve the overall well-being of individuals on opioid therapy while ensuring effective pain management.
The major global manufacturers of Opioid-Induced Constipation include Ironwood Pharmaceuticals, Daiichi Sankyo, Pfizer, Progenics Pharmaceuticals, Shionogi, Allergan, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma, Mundipharma International, Ono Pharmaceutical, Takeda Pharmaceutical Company, Theravance Biopharma, Bausch Health, Cosmo Pharmaceuticals, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Opioid-Induced Constipation. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Opioid-Induced Constipation market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Opioid-Induced Constipation market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Opioid-Induced Constipation industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Opioid-Induced Constipation Include:
Ironwood Pharmaceuticals
Daiichi Sankyo
Pfizer
Progenics Pharmaceuticals
Shionogi
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International
Ono Pharmaceutical
Takeda Pharmaceutical Company
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Opioid-Induced Constipation Product Segment Include:
Lubiprostone
Methylnaltrexone Bromide
Naldemedine
Alvimopan
Others
Opioid-Induced Constipation Product Application Include:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Opioid-Induced Constipation Industry PESTEL Analysis
Chapter 3: Global Opioid-Induced Constipation Industry Porter's Five Forces Analysis
Chapter 4: Global Opioid-Induced Constipation Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis
Chapter 5: Global Opioid-Induced Constipation Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 6: Global Opioid-Induced Constipation Sales, Revenue, Price and Forecast by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 8: Industrial Chain Analysis, Opioid-Induced Constipation Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Opioid-Induced Constipation Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Opioid-Induced Constipation Product by Type
- 1.2.1 Lubiprostone
- 1.2.2 Methylnaltrexone Bromide
- 1.2.3 Naldemedine
- 1.2.4 Alvimopan
- 1.2.5 Others
- 1.3 Opioid-Induced Constipation Product by Application
- 1.3.1 Hospital Pharmacy
- 1.3.2 Retail Pharmacy
- 1.3.3 Online Pharmacy
- 1.4 Global Opioid-Induced Constipation Market Revenue and Sales Analysis
- 1.4.1 Global Opioid-Induced Constipation Revenue Market Size Analysis (2020-2032)
- 1.4.2 Global Opioid-Induced Constipation Sales Market Size Analysis (2020-2032)
- 1.4.3 Global Opioid-Induced Constipation Market Sales Price Trend Analysis (2020-2032)
- 1.5 Opioid-Induced Constipation Market Development Status and Trends
- 1.5.1 Opioid-Induced Constipation Industry Development Status Analysis
- 1.5.2 Opioid-Induced Constipation Industry Development Trends Analysis
- 2 Opioid-Induced Constipation Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Opioid-Induced Constipation Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Opioid-Induced Constipation Market Analysis by Country
- 4.1 Global Opioid-Induced Constipation Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Opioid-Induced Constipation Revenue and Market Share by Country (2020-2025)
- 4.1.2 Global Opioid-Induced Constipation Revenue and Market Share Forecast by Country (2026-2032)
- 4.2 Global Opioid-Induced Constipation Sales Analysis by Country: 2024 VS 2025 VS 2032
- 4.2.1 Global Opioid-Induced Constipation Sales and Market Share by Country (2020-2025)
- 4.2.2 Global Opioid-Induced Constipation Sales and Market Share Forecast by Country (2026-2032)
- 4.3 United States Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.4 Germany Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.5 Japan Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.6 China Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.7 France Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.8 U.K. Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.9 South Korea Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.10 Canada Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.11 Italy Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.12 Russia Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.13 Mexico Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.14 Brazil Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.15 India Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.16 Vietnam Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.17 Thailand Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 4.18 South Africa Opioid-Induced Constipation Market Sales, Revenue and Growth Rate (2020-2032)
- 5 Competition by Manufacturers
- 5.1 Global Opioid-Induced Constipation Market Sales, Revenue and Sales Price by Key Manufacturers (2021-2025)
- 5.1.1 Global Opioid-Induced Constipation Market Sales by Key Manufacturers (2021-2025)
- 5.1.2 Global Opioid-Induced Constipation Market Revenue by Key Manufacturers (2021-2025)
- 5.1.3 Global Opioid-Induced Constipation Average Sales Price by Manufacturers (2021-2025)
- 5.2 Opioid-Induced Constipation Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Opioid-Induced Constipation Competitive Landscape Analysis
- 5.2.2 Global Key Manufacturers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Opioid-Induced Constipation Market Analysis by Type
- 6.1 Global Opioid-Induced Constipation Market Revenue Analysis by Type
- 6.1.1 Global Opioid-Induced Constipation Market Size Analysis by Type: 2024 & 2025 & 2032
- 6.1.2 Global Opioid-Induced Constipation Revenue and Forecast Analysis by Type (2020-2032)
- 6.2 Global Opioid-Induced Constipation Market Sales and Forecast Analysis by Type (2020-2032)
- 6.3 Global Opioid-Induced Constipation Sales Price Trend Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Ironwood Pharmaceuticals
- 7.1.1 Ironwood Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Ironwood Pharmaceuticals Opioid-Induced Constipation Product Portfolio
- 7.1.3 Ironwood Pharmaceuticals Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.2 Daiichi Sankyo
- 7.2.1 Daiichi Sankyo Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
- 7.2.3 Daiichi Sankyo Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.3 Pfizer
- 7.3.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Pfizer Opioid-Induced Constipation Product Portfolio
- 7.3.3 Pfizer Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.4 Progenics Pharmaceuticals
- 7.4.1 Progenics Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
- 7.4.3 Progenics Pharmaceuticals Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.5 Shionogi
- 7.5.1 Shionogi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Shionogi Opioid-Induced Constipation Product Portfolio
- 7.5.3 Shionogi Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.6 Allergan
- 7.6.1 Allergan Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Allergan Opioid-Induced Constipation Product Portfolio
- 7.6.3 Allergan Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.7 Nektar Therapeutics
- 7.7.1 Nektar Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
- 7.7.3 Nektar Therapeutics Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.8 Purdue Pharma
- 7.8.1 Purdue Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Purdue Pharma Opioid-Induced Constipation Product Portfolio
- 7.8.3 Purdue Pharma Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.9 S.L.A. Pharma
- 7.9.1 S.L.A. Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 S.L.A. Pharma Opioid-Induced Constipation Product Portfolio
- 7.9.3 S.L.A. Pharma Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.10 Mundipharma International
- 7.10.1 Mundipharma International Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Mundipharma International Opioid-Induced Constipation Product Portfolio
- 7.10.3 Mundipharma International Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.11 Ono Pharmaceutical
- 7.11.1 Ono Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 Ono Pharmaceutical Opioid-Induced Constipation Product Portfolio
- 7.11.3 Ono Pharmaceutical Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.12 Takeda Pharmaceutical Company
- 7.12.1 Takeda Pharmaceutical Company Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Takeda Pharmaceutical Company Opioid-Induced Constipation Product Portfolio
- 7.12.3 Takeda Pharmaceutical Company Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.13 Theravance Biopharma
- 7.13.1 Theravance Biopharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 Theravance Biopharma Opioid-Induced Constipation Product Portfolio
- 7.13.3 Theravance Biopharma Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.14 Bausch Health
- 7.14.1 Bausch Health Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.14.2 Bausch Health Opioid-Induced Constipation Product Portfolio
- 7.14.3 Bausch Health Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.15 Cosmo Pharmaceuticals
- 7.15.1 Cosmo Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.15.2 Cosmo Pharmaceuticals Opioid-Induced Constipation Product Portfolio
- 7.15.3 Cosmo Pharmaceuticals Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.16 Daewoong Pharmaceutical
- 7.16.1 Daewoong Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.16.2 Daewoong Pharmaceutical Opioid-Induced Constipation Product Portfolio
- 7.16.3 Daewoong Pharmaceutical Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.17 C.B. Fleet Company
- 7.17.1 C.B. Fleet Company Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.17.2 C.B. Fleet Company Opioid-Induced Constipation Product Portfolio
- 7.17.3 C.B. Fleet Company Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.18 Sucampo Pharmaceuticals
- 7.18.1 Sucampo Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.18.2 Sucampo Pharmaceuticals Opioid-Induced Constipation Product Portfolio
- 7.18.3 Sucampo Pharmaceuticals Opioid-Induced Constipation Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Opioid-Induced Constipation Industry Chain Analysis
- 8.2 Opioid-Induced Constipation Industry Upstream Supply Analysis
- 8.2.1 Upstream Key Raw Material Supply Analysis
- 8.2.2 Raw Material Suppliers and Contact Information
- 8.3 Opioid-Induced Constipation Product Downstream Application Analysis
- 8.3.1 Global Opioid-Induced Constipation Revenue Market Size by Application: 2024 & 2025 & 2032
- 8.3.2 Global Opioid-Induced Constipation Revenue and Forecast Analysis by Application (2020-2032)
- 8.3.3 Global Opioid-Induced Constipation Sales and Forecast Analysis by Application (2020-2032)
- 8.4 Opioid-Induced Constipation Typical Downstream Customers
- 8.5 Opioid-Induced Constipation Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
